Board considered and recommended the re-appointment of Ms. Priya Gandhi as Executive Director of the Company for the period of 3 years with effect from 28 October 2026, subject to approval ....
HESTERBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts more than Nifty Microcap 250 and 4.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Hester Biosciences reported strong FY26 results with standalone revenue of INR 2,921.36 million (up 2% YoY) and standalone profit after tax of INR 521.00 million (up 63.7% YoY). Consolidated revenue stood at INR 3,325.99 million with consolidated PAT of INR 574.84 million, up 99.4% YoY. The Board recommended a dividend of INR 11 per share (110%) for FY26, subject to shareholder approval. Additionally, the Board approved the re-appointment of Ms. Priya Gandhi as Executive Director for 3 years from 28 October 2026. The company also completed divestment of its Texas Lifescience Private Limited subsidiary in March 2026. Statutory auditors Chandulal M. Shah & Co. issued an unmodified opinion on the financial results.
Strong profitability growth and dividend recommendation are positive signals for shareholders. The re-appointment of a promoter family member (daughter of CEO) to the board maintains leadership continuity.